Centessa Pharmaceuticals
8 known investors
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. It focuses on drug development for patients with these conditions.
Investors · 8
Competitors · 2
by search overlapBioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Centessa Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Centessa Pharmaceuticals do?
- Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. It focuses on drug development for patients with these conditions.
- Who are Centessa Pharmaceuticals's investors?
- Centessa Pharmaceuticals's investors include Advent Life Sciences, EcoR1 Capital, Foresite Capital, Medicxi, Oberland Capital, Scion Life Sciences, Vida Ventures, Cambridge Innovation Capital.